Critical Path Institute Unveils New Coalition to Propel Human-Relevant Drug
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.3 Articles
3 Articles
Critical Path Institute Unveils New Coalition to Propel Human-Relevant Drug
TUCSON, Ariz., and AMSTERDAM — May 19, 2026 — In a transformative step for drug development and regulatory science, the Critical Path Institute (C-Path) has officially launched the New Approach Methodologies Developer Coalition (NAMs-DC). This novel initiative is a precompetitive, public-private partnership uniting companies dedicated to the creation and optimization of new approach methodologies (NAMs). […]
CN Bio Participating in a New Critical Path Institute Coalition of New Approach Methodologies Developers (NAMs-DC) to Support Advancement in Drug Development
CN bio is proud to be part of a new Critical Path Institute (C-Path) New approach Methodologies Developers Coalition (NAMs-DC), which brings together developers to fast-track the validation, qualification and regulatory adoption of NAMs for improved drug development efficiency and reduced reliance on animals. View the TUCSON, Ariz., and AMSTERDAM, Press Release Who is C-Path? C-Path is globally recognized as a pioneer in accelerating drug devel…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
